ProKidney Corp.
ProKidney Corp. (PROK) Stock Overview
Explore ProKidney Corp.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.5B
P/E Ratio
-9.85
EPS (TTM)
$-0.59
ROE
0.07%
PROK Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of ProKidney Corp. (PROK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 43.86, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.36.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -9.85 and a market capitalization of 1.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Bruce Culleton
204
2000 Frontis Plaza Blvd., Winston-Salem, NC
2021